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Abstract
Background Higher body mass index (BMI) and waist-to-hip ratio (WHR) increase the risk of cardiovascular disease, but
the extent to which this is mediated by blood pressure, diabetes, lipid traits, and smoking is not fully understood.
Methods Using consortia and UK Biobank genetic association summary data from 140,595 to 898,130 participants pre-
dominantly of European ancestry, Mendelian randomization mediation analysis was performed to investigate the degree to
which systolic blood pressure (SBP), diabetes, lipid traits, and smoking mediated an effect of BMI and WHR on the risk of
coronary artery disease (CAD), peripheral artery disease (PAD) and stroke.
Results The odds ratio of CAD per 1-standard deviation increase in genetically predicted BMI was 1.49 (95% CI 1.39 to
1.60). This attenuated to 1.34 (95% CI 1.24 to 1.45) after adjusting for genetically predicted SBP (proportion mediated 27%,
95% CI 3% to 50%), to 1.27 (95% CI 1.17 to 1.37) after adjusting for genetically predicted diabetes (41% mediated, 95% CI
18% to 63%), to 1.47 (95% CI 1.36 to 1.59) after adjusting for genetically predicted lipids (3% mediated, 95% −23% to
29%), and to 1.46 (95% CI 1.34 to 1.58) after adjusting for genetically predicted smoking (6% mediated, 95% CI −20% to
32%). Adjusting for all the mediators together, the estimate attenuated to 1.14 (95% CI 1.04 to 1.26; 66% mediated, 95% CI
42% to 91%). A similar pattern was observed when considering genetically predicted WHR as the exposure, and PAD or
stroke as the outcome.
Conclusions Measures to reduce obesity will lower the risk of cardiovascular disease primarily by impacting downstream
metabolic risk factors, particularly diabetes and hypertension. Reduction of obesity prevalence alongside control and
management of its mediators is likely to be most effective for minimizing the burden of obesity.
Background
Cardiovascular disease (CVD) is the leading cause of death
and disability worldwide [1]. Obesity can contribute
towards CVD risk through effects on hyperglycaemia,
hypertension, dyslipidaemia, and smoking behaviour [2–5].
The global prevalence of obesity has more than tripled in
the last 40 years, with an even greater rise in incidence
amongst children [6]. It is estimated that by 2030,
approximately half of the US population will be obese [7].
While obesity prevention remains the priority, there are also
treatments available to effectively manage the downstream
mediators through which obesity causes CVD [8–11].
Understanding such pathways is therefore paramount to
reducing cardiovascular risk.
Obesity can be measured by various means. It is
defined by the World Health Organisation as a body mass
index (BMI) greater than or equal to 30 kg/m2 [12],
although this cut-off threshold can vary between different
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populations. However, BMI is not a direct measure of
adiposity and is also correlated with fat-free mass [12].
Assessment of obesity using the waist-to-hip ratio (WHR)
is less subject to influence from height and muscle mass
and is positively associated with cardiovascular risk in
individuals with a normal BMI [13, 14]. Thus, BMI and
WHR represent distinct measures of body fat that may
differentially affect the risk of CVD outcomes. Conven-
tional observational studies have shown that the rela-
tionship between obesity measures such as BMI and WHR
with CVD is attenuated when adjustment is made for
cardiometabolic risk factors such as blood pressure, lipid
traits or measures of glycaemia [15]. This has allowed for
estimation of the proportion of the effect of obesity that is
mediated through these intermediates [15]. However, such
observational analysis is vulnerable to bias from envir-
onmental confounding factors and measurement error,
both of which can result in underestimation of the pro-
portion of effect mediated [16, 17]. The Mendelian ran-
domization (MR) approach uses genetic variants as
instruments for studying the effect of modifying an
exposure on an outcome and has now been extended to
perform mediation analyses [16, 18]. Such use of genetic
variants whose allocation is not affected by environmental
confounding factors means that MR estimates are less
vulnerable to confounding from environmental factors.
Furthermore, the use of genetic variants that are asso-
ciated with the exposure (BMI or WHR) in large popu-
lations including individuals of different ages means that
their association estimates are typically less vulnerable to
measurement error or variation related to the timing of
measurement [16].
The increasing availability of large-scale genome-wide
association study (GWAS) data has greatly facilitated MR
analyses considering cardiovascular risk factors and out-
comes. In this study, we aimed to use such data within the
MR framework to investigate the role of blood pressure,
diabetes, fasting glucose, lipid traits, and smoking in
mediating the effect of BMI and WHR on coronary artery
disease (CAD), peripheral arterial disease (PAD) and
stroke risk.
Methods
Ethical approval, data availability, code availability
and reporting
The data used in this work are publicly available and the
studies from which they were obtained are cited. All these
studies obtained relevant participant consent and ethical
approval. The results from the analyses performed in this
work are presented in the main manuscript or its
supplementary files. All code used for this work is
available upon reasonable request to the corresponding
author. This paper has been reported based on recom-
mendations by the STROBE-MR Guidelines (Research
Checklist) [19]. The study protocol and details were not
pre-registered.
Data sources
Genetic association estimates for BMI and WHR were
obtained from the GIANT Consortium GWAS meta-
analysis of 806,834 and 697,734 European-ancestry indi-
viduals, respectively [20]. Genetic association estimates
for systolic blood pressure (SBP) were obtained from a
GWAS of 318,417 White British individuals in the UK
Biobank, with the correction made for any self-reported
anti-hypertensive medication use by adding 10 mmHg to
the mean SBP measured from two automated recordings
that were taken 2 min apart at baseline assessment [21].
Previous methodological work has supported that the
addition of a constant value to the observed blood pressure
in individuals taking antihypertensive medication as a
strategy that optimises statistical power while minimising
bias [22]. Genetic association estimates for lifetime
smoking (referred to hereon as smoking) were obtained
from a GWAS of 462,690 European-ancestry individuals
in the UK Biobank [23]. A lifetime measure of smoking
was created based on self-reported age at initiation, age at
cessation and cigarettes smoked per day [23]. Genetic
association estimates for liability to diabetes came from
the DIAGRAM Consortium GWAS meta-analysis of
74,124 cases and 824,006 controls, all of the European
ancestry [24]. Genetic association estimates for plasma
fasting glucose were obtained by using PLINK software to
carry out a meta-analysis of MAGIC Consortium GWAS
summary data from separate analyses of 67,506 men and
73,089 women who were not diabetic [25, 26]. Genetic
association estimates for fasting serum low-density lipo-
protein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C) and triglycerides were obtained from
the Global Lipids Genetics Consortium GWAS of 188,577
European-ancestry individuals [27]. Genetic association
estimates for CAD were obtained from the CARDIo-
GRAMplusC4D Consortium 1000G multi-ethnic GWAS
(77% European-ancestry) of 60,801 cases and 123,504
controls [28]. Genetic association estimates for PAD were
obtained from the Million Veterans Programme multi-
ethnic (72% European-ancestry) GWAS of 31,307 cases
and 211,753 controls [29]. Genetic association estimates
for stroke were obtained from the MEGASTROKE multi-
ethnic (86% European-ancestry) GWAS of 67,162 cases
(of any stroke) and 454,450 controls [30]. Population
characteristics and specific trait definitions relating to all
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these summary genetic association estimates are available
in their original publications. For the analyses performed
in this current work, genetic variants from different studies
were aligned by their effect alleles and no exclusions were
made for palindromic variants. Only variants for which
genetic association estimates were available for all the
traits being investigated in any given analysis were con-
sidered. In order to maintain consistency in the variants
employed as instruments across different analyses, proxies
were not used.
Instrument selection
To estimate the total effect of BMI and WHR, respectively
on the considered cardiovascular outcomes, instruments
were selected as single-nucleotide polymorphisms (SNPs)
that associated with BMI or WHR at genome-wide sig-
nificance (P < 5 × 10−8) and were in pair-wise linkage
disequilibrium (LD) r2 < 0.001. The percentage variance in
BMI and WHR explained by the variants selected as their
respective instruments was estimated as previously
described [31]. To select instruments for mediation ana-
lysis, all SNPs related to the considered exposure (BMI or
WHR) or mediators at genome-wide significance were
pooled and clumped to pairwise LD r2 < 0.001 based on
the lowest P-value for association with any trait. All
clumping was performed using the TwoSampleMR pack-
age in R [32].
Total effects
Random-effects inverse-variance weighted (IVW) MR
was used as the main analysis for estimating the total
effects of genetically predicted BMI and genetically
predicted WHR respectively on each of the considered
CVD outcomes [33]. The contamination-mixture
method, weighted median and MR-Egger were used in
sensitivity analyses to explore the robustness of the
findings to potential pleiotropic effects of the variants
[34–36]. The contamination-mixture model makes the
assumption that MR estimates from valid instruments
follow a normal distribution that centres on the true
causal effect estimate, while those calculated from
invalid instrument variants follow a normal distribution
centred on the null [35]. This allows for a likelihood
function to be specified and maximized when allocating
each variant to one of the two mixture distributions [35].
The weighted median approach orders the MR estimates
from individual variants by their magnitude weighted for
their precision and selects the median as the overall MR
estimate, calculating standard error by bootstrapping
[34]. MR-Egger regresses the variant-outcome associa-
tion estimates against the variant-exposure association
estimates, weighted for the precision of the variant-
outcome estimates [36]. It gives a valid MR estimate and
test for the presence of directional pleiotropy in scenarios
where any direct effect of the variants on the outcome is
not correlated to their association with the exposure [36].
The MendelianRandomization package (version 0.4.2) in
R (version 3.6.3) was used for performing the IVW,
contamination-mixture, weighted median MR and MR-
Egger analyses [37].
Mediation analysis
To estimate the direct effect of genetically predicted BMI
and genetically predicted WHR on each of the three con-
sidered CVD outcomes that were not being mediated by the
investigated intermediary risk factors, summary data mul-
tivariable MR was performed [38–40]. Specifically, the
orientations of all genetic association estimates were har-
monized and the variant-outcome genetic association esti-
mates were regressed on the variant-exposure and variant-
mediator estimates, weighted for the precision of the
variant-outcome association, with the intercept fixed to zero
[40]. Using this approach, adjustment was made for
genetically predicted SBP, diabetes, smoking and lipid traits
(LDL-C, HDL-C and triglycerides together) in turn, and
finally including all mediators together in a joint model. In a
sensitivity analysis, genetically predicted diabetes was
excluded from this joint model to remove any bias that
might be introduced because of its binary nature [41]. For
analyses considering genetically predicted fasting glucose
in non-diabetics instead of genetically predicted diabetes,
the corresponding genetic association data were substituted.
Diabetes and fasting glucose were not included together in
the same model.
Multivariable MR mediation analysis was performed to
estimate the proportion of the effect of BMI and WHR
respectively on CAD, PAD and stroke that was mediated
through each of the considered risk factors, and also all of
them together [16]. Specifically, the direct effect of
genetically predicted BMI and genetically predicted WHR
respectively were divided by their total effect and sub-
tracted from 1, with standard errors estimated using the
propagation of error method [16, 18].
Independent effects of genetically predicted BMI
and WHR
The direct effects of genetically predicted BMI and
genetically predicted WHR on the considered CVD out-
comes that are not mediated through each other were
measured by including only these two traits together as
exposures in the summary data multivariable MR model
described above.
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Results
Total effects
The variants selected as instruments for BMI and WHR
explain 5.7% and 3.6% of their variance respectively.
Considering total effects, there was consistent evidence
across the IVW, contamination-mixture, weighted median
and MR-Egger methods that both higher genetically pre-
dicted BMI and higher genetically predicted WHR
increased CAD, PAD and stroke risk (Supplementary Fig.
1). The confidence intervals of the MR-Egger estimates
were wider than for the other methods, consistent with its
lower statistical power [42]. The MR-Egger intercept did
not provide evidence to suggest directional pleiotropy in
any analysis (P > 0.05 in all analyses). In the main IVW MR
analysis, the odds ratio per 1-standard deviation (SD)
increase in genetically predicted BMI (4.81 kg/m2) for CAD
risk was 1.49 (95% confidence interval [CI] 1.39 to 1.60),
for PAD risk was 1.70 (95% CI 1.58 to 1.82), and for stroke
risk was 1.22 (95% CI 1.15 to 1.29). For a 1-SD increase in
genetically predicted WHR (0.09), this was 1.54 (95% CI
1.38 to 1.71) for CAD risk, 1.55 (95% CI 1.40 to 1.71) for
PAD risk, and 1.30 (95% CI 1.21 to 1.40) for stroke risk.
Mediation analysis
There was attenuation in the associations of genetically
predicted BMI and genetically predicted WHR with the
three CVD outcomes after adjusting for genetically pre-
dicted SBP, diabetes, lipid traits (LDL-C, HDL-C and tri-
glycerides together) and smoking, either separately or in the
same joint model (Fig. 1). The 49% (95% CI 39% to 60%)
increased risk of CAD conferred per 1-SD increase in
genetically predicted BMI attenuated to 34% (95% CI 24%
to 45%) after adjusting for genetically predicted SBP, to
27% (95% CI 17% to 37%) after adjusting for genetically
predicted diabetes, to 47% (95% CI 36% to 59%) after
adjusting for genetically predicted lipids, and to 46% (95%
CI 34% to 58%) after adjusting for genetically predicted
smoking. Adjusting for all the mediators together in the
same model, the association attenuated to 14% (95% CI 4%
to 26%).
The percentage attenuation in the total effects of
genetically predicted BMI and WHR respectively on the
three CVD outcomes after adjusting for the mediators is
depicted in Fig. 2. For the effect of genetically predicted
BMI on CAD risk, 27% (95% CI 3% to 50%) was mediated
by genetically predicted SBP, 41% (95% 18% to 63%) was
mediated by genetically predicted diabetes, 3% (−23% to
29%) was mediated by genetically predicted lipids, and 6%
(95% CI −20% to 32%) was mediated by genetically pre-
dicted smoking. All the mediators together accounted for
66% (95% CI 42% to 91%) of the total effect of genetically
predicted BMI on CAD risk.
A joint model including all considered mediators
except genetically predicted diabetes was also constructed
(Supplementary Fig. 2). Adjusting together for all the
mediators except genetically predicted diabetes, the
association of genetically predicted BMI with CAD risk
attenuated from odds ratio 1.49 (95% CI 1.39 to 1.60) to
1.27 (95% CI 1.16 to 1.40).
There was little change in the association of either
genetically predicted BMI or genetically predicted WHR
with risk of the three CVD outcomes after adjusting for
genetically predicted fasting glucose in non-diabetic indi-
viduals (Fig. 3).
Independent effects of genetically predicted BMI
and WHR
Both genetically predicted BMI and genetically predicted
WHR had direct effects on CAD, PAD and stroke after
mutual adjustment (Fig. 4). The increased CAD risk
attributed to a 1-SD higher genetically predicted BMI
attenuated from 49% (95% CI 39% to 60%) to 32% (95%
CI 20% to 45%) after adjusting for genetically predicted
WHR, and the increased CAD risk attributed to a 1-SD
higher genetically predicted WHR attenuated from 54%
(95% CI 38% to 71%) to 33% (95% CI 18% to 50%) after
adjusting for genetically predicted BMI.
Discussion
This study uses large-scale genetic association data within
the MR paradigm to investigate the role of SBP, diabetes,
lipid traits and smoking in mediating the effect of BMI and
WHR on CAD, PAD and stroke risk. The results support
that the majority of the effects of obesity on CVD are
mediated through these risk factors, with diabetes and
blood pressure being the most notable and accounting for
approximately one-third and one-quarter of the effect
respectively. In contrast, the analysis of genetically pre-
dicted fasting glucose in non-diabetic individuals did not
provide any evidence to support its role in mediating the
effect of obesity on CVD risk. Previous work has sup-
ported an effect of diabetes liability, fasting glucose and
glycated haemoglobin on CVD risk [43, 44]. Taken
together with our current findings, this suggests that obe-
sity may be affecting CVD risk by increasing diabetes
liability and non-fasting (postprandial) glucose levels.
Similarly, while lipid traits are known to affect CVD risk
[45], our current study suggests that obesity is conferring
only a small proportion of its effect on CVD risk through
this pathway. Consistent with this, previous work has
D. Gill et al.
supported an effect of BMI on HDL-C and triglyceride
levels, but not LDL-C [44].
In our analyses, the sum of the estimated mediating
effects of the various risk factors considered individually
was comparable to their total mediating effect estimated
when considering them all together in the same model,
consistent with them acting through distinct mechanisms.
Including genetically predicted BMI and genetically pre-
dicted WHR in the same model produced evidence con-
sistent with these traits having direct effects on CVD risk
independently of each other. It follows that rather than
analysing BMI or WHR alone, they should be considered
together as they capture different aspects of adiposity.
Our findings have important clinical and public health
implications. Behavioural interventions to reduce obesity
can have inadequate long term effects [46], pharmacological
treatments may be limited by unfavourable adverse effect
profiles [47], and surgical procedures are often reserved for
only severe cases [48]. While preventing obesity remains
the priority, this work supports that the majority of its
cardiovascular consequences may also be managed by
effectively controlling its downstream mediators, most
notably diabetes and raised blood pressure, for which
effective pharmacological interventions are available. This
has relevance for the more than 640 million individuals
worldwide currently living with obesity [49], and the many
more forecasted to become obese in coming years [50].
Such holistic consideration of obesity together with its
mediators could contribute to a shift from the single-disease
focus of health systems towards prioritizing multi-morbidity
and promoting individual and societal wellness [51].
Our analyses were also suggestive of some possible
residual effect of BMI on CVD risk even after adjusting for
all the considered mediating risk factors, consistent with
metabolically healthy obesity still conferring increased
CVD risk [52]. In contrast, the investigation of WHR was
consistent with an absence of any direct effect on CVD risk
after accounting for all mediating risk factors together,
suggesting that WHR may be entirely influencing CVD
through downstream metabolic traits. Taken together, these
results suggest that unless the growing obesity epidemic is
effectively tackled, we risk undoing the large reductions in
Fig. 1 Direct effects of genetically predicted body mass index
(BMI) and genetically predicted waist-to-hip ratio (WHR) on
coronary artery disease (CAD), peripheral artery disease (PAD)
and stroke, estimated after adjusting for genetic liability to med-
iators separately and together in the same model. The y-axis details
the genetically predicted mediator(s) for which adjustments were
made. Blood pressure refers to systolic blood pressure. Lipids refer to
serum low-density lipoprotein cholesterol, high-density lipoprotein
cholesterol and triglycerides considered together in one model. CI
confidence interval, OR odds ratio, SD standard deviation.
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CVD mortality achieved over past decades [1]. Population-
based approaches that decrease obesity by addressing key
upstream drivers such as poor diet and physical inactivity
have substantial potential for impact and are also effective
for reducing health inequalities [53, 54].
The results of our current study can be contrasted to
those from a large-scale observational analysis of 1.8 mil-
lion people across 97 studies [15, 55]. This previous work
estimated that 46% (95% CI 42% to 50%) of the excess risk
conferred by raised BMI on CAD and 76% (95% CI 65% to
Fig. 2 Proportion (as a percentage) of the respective effects of
genetically predicted body mass index (BMI) and genetically
predicted waist-to-hip ratio (WHR) on coronary artery disease
(CAD), peripheral artery disease (PAD) and stroke that are
mediated through the genetically predicted risk factors
individually and together. The y-axis details the genetically predicted
mediator(s) for which adjustment was made. Blood pressure refers to
systolic blood pressure. Lipids refer to serum low-density lipoprotein
cholesterol, high-density lipoprotein cholesterol and triglycerides
considered together in one model. CI confidence interval.
Fig. 3 Direct effects of body mass index (BMI) and waist-to-hip
ratio (WHR) on coronary artery disease (CAD), peripheral artery
disease (PAD) and stroke, estimated after no adjustment and after
adjustment for genetically predicted fasting glucose in non-
diabetics. CI confidence interval, OR odds ratio, SD standard
deviation.
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91%) on stroke were mediated by effects on blood pressure,
glucose levels and lipid traits, with blood pressure being the
most important and mediation for stroke being greatest [15].
However, the approach and data used in our current study
offer a number of possible improvements. Our work
includes a greater repertoire of risk factors and CVD out-
comes than have been considered together previously
[15, 44], in particular, drawing on recently available GWAS
summary data to study smoking and PAD [23, 29]. MR
analysis uses randomly allocated genetic variants that
represent a lifelong cumulative liability to the traits for
which they serve as instruments and can therefore help
overcome the environmental confounding that may bias
conventional observational studies [16]. Consistent with
this, our MR results indicate that these risk factors mediate a
greater proportion of the effect of obesity than suggested by
previous conventional observational analyses [15]. Fur-
thermore, our MR estimates are comparable to those
obtained in previous MR studies considering BMI and
WHR as exposures and different types of CVD as the
outcome [44, 56, 57].
Also of relevance here, we considered a genetic liability
to diabetes and genetically predicted fasting glucose in
non-diabetic individuals as separate risk factors. Our
findings support the concept that obesity traits confer an
increased risk of CVD specifically through liability to
diabetes, rather than variation in fasting glucose levels
within the normal physiological range. This is important
because fasting glucose may have a non-linear association
with CVD risk [58], only having detrimental effects
beyond a certain point [59].
Our current study also has limitations. The aim of the
current work was to investigate the degree to which cardi-
ometabolic traits mediate the effects of BMI and WHR on
CVD outcomes, and our study did not extend to investigate
any possible role of BMI or WHR in mediating the effects
of the considered cardiometabolic traits on CVD risk. The
genetic association data used in this work are drawn from
predominantly European populations, and should therefore
be interpreted with caution when extrapolating to other
ethnic groups. Diabetes is a binary outcome, and as such
our consideration of genetically predicted diabetes could
introduce bias into the mediation analysis because not all
individuals possessing such genetic liability to develop
diabetes-related traits [41]. SBP was used as a proxy for
studying the effects of blood pressure more generally.
Given the high degree of phenotypic and genetic correlation
between blood pressure traits [60], this would seem unlikely
to affect the conclusions drawn. A theoretical weakness of
the MR approach relates to bias from pleiotropic effects of
the genetic variants incorporated as instruments for the traits
under study, whereby they may directly affect the outcome
through pathways independent of the exposure or mediators
being considered. Although such bias cannot be entirely
excluded, it is reassuring that we obtained similar MR
estimates for the total effect of BMI and WHR respectively
on the three CVD outcomes when performing the IVW,
contamination-mixture, weighted median and MR-Egger
methods that each make different assumptions concerning
the presence of pleiotropic variants [42]. Finally, there is
currently no available method for assessing instrument
strength within the two-sample multivariable MR setting,
and we could therefore not assess potential vulnerability to
weak instrument bias [38].
In conclusion, this work using the MR framework sug-
gests that the majority of the effects of obesity on CVD risk
are mediated through metabolic risk factors, most notably
diabetes and blood pressure. Comprehensive public health
measures that target the reduction of obesity prevalence
alongside control and management of its downstream
mediators are likely to be most effective for minimizing the
burden of obesity on individuals and health systems alike.
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